RxDoctor Payments Data

Heather Elliott

Family · Rocky Ford, CONPI 1003233479

Payments from drug & device makers

$2,117in general payments, 2019–2025

Across 113 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$727
  • AstraZeneca$211
  • Novo Nordisk$209
  • Pfizer$203
  • Lilly USA, LLC$175
  • Otsuka America Pharmaceutical, Inc.$135
  • plus $458 from 11 others

What the payments were for

  • Food & beverage$2,10699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,117 in reported general payments places this provider in the 85th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$100,701
XifaxanRifaximin32$81,009
Tresiba Flextouch U-200Insulin Degludec16$46,061
EliquisApixaban52$45,025
MounjaroTirzepatide30$41,857
FarxigaDapagliflozin Propanediol48$41,543
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$37,771
UbrelvyUbrogepant15$36,909
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$27,425
VraylarCariprazine Hcl19$26,215
Aimovig AutoinjectorErenumab-Aooe24$24,407
RybelsusSemaglutide15$23,327
MyrbetriqMirabegron22$21,395
SymbicortBudesonide/Formoterol Fumarate60$19,926
XareltoRivaroxaban31$17,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$209$124,028115 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$211$104,441153 claims
AbbVieUbrelvy, Vraylar, Qulipta, Synthroid$727$77,39271 claims
PfizerEliquis, Premarin$203$53,64975 claims
Lilly USA, LLCMounjaro$175$41,85730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,182 family providers in Colorado.

Other family in Rocky Ford

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →